New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 28, 2014
06:31 EDTVRX, JNJ, AGN, NSRGYValeant prepared to make higher offer for Allergan, says Wells Fargo
Wells Fargo said it left Valeant (VRX) and Pershing Square's sell-side meeting Friday with the impression that Valeant is prepared to go higher than the current offer for Allergan (AGN), which it notes is about $159 per share at closing prices on April 25. Wells pointed out that Valeant and Pershing indicated that Nestle (NSRGY) was the most likely potential additional bidder for Allergan followed by Johnson & Johnson (JNJ). Wells has an Outperform rating on Allergan.
News For AGN;VRX;NSRGY;JNJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
February 19, 2015
05:36 EDTNSRGYNestle aims to achieve organic growth of around 5%
Subscribe for More Information
05:35 EDTNSRGYNestle reports FY14 organic growth of 4.5%
Nestlé'sFY14 organic growth was 4.5%, composed of 2.3% real internal growth and 2.2% pricing. Sales were CHF 91.6B, down 0.6%, impacted by negative foreign exchange of -5.5%. Acquisitions, net of divestitures, added 0.4% to sales.
February 18, 2015
16:46 EDTAGN, JNJOn The Fly: Closing Wrap
Subscribe for More Information
12:36 EDTJNJAnalysts applaud cheaper than expected Boston Scientific settlement
Subscribe for More Information
12:31 EDTAGN, JNJOn The Fly: Midday Wrap
Subscribe for More Information
09:48 EDTAGNActavis Q4 'exceptional,' taking Allergan name 'wise,' says BMO Capital
BMO Capital says Actavis (ACT) is "firing on all cylinders" after reporting "exceptional" Q4 earnings on the strength of the company's North American Generics and International segment. BMO views the decision to adopt the Allergan (AGN) name as "wise" given the Botox maker's strong reputation. The firm keeps an Outperform rating on Actavis.
07:50 EDTAGNActavis CEO says company gave appropriate guidance to analysts
Actavis (ACT) CEO Saunders said he believes that the company did provide appropriate guidance to analysts ahead of its earnings beat. Saunders sees the Allergan (AGN) deal closing by the end of this quarter or early next quarter. Saunders says tying R&D to a percentage of revenue "makes no sense to me," noting that Actavis will spend about $1.7B on R&D next year. Saunders says will do acquisition if opportunity arises, but not planning for M&A right now. Actavis CEO Brent Saunders is speaking on CNBC.
07:41 EDTJNJSettlement 'a big win' for Boston Scientific, says Bernstein
Subscribe for More Information
07:12 EDTJNJBoston Scientific settlement should remove overhang, says Stifel
Subscribe for More Information
07:09 EDTJNJBoston Scientific payment to J&J well below expectations, says Piper Jaffray
Subscribe for More Information
07:01 EDTAGNActavis announces intention to adopt 'Allergan' corporate name
Subscribe for More Information
06:34 EDTAGNActavis sees Allergan transaction completed in late Q1 or early Q2
February 17, 2015
18:17 EDTVRXJANA Partners gives quarterly update on stakes
NEW STAKES: NCR (NCR), Liberty Ventures (LVNTA), Solarcity (SCTY), Computer Sciences Corp (CSC), Salix (SLXP), and Applied Materials (AMAT). INCREASED STAKES: Hertz (HTZ), Valeant (VRX), Walgreens Boots Alliance (WBA), Rackspace (RAX), and HD Supply (HDS). DECREASED STAKES: AIG (AIG), Actavis (ACT), Charter (CHTR), AerCap (AER), and Energy Transfer Equity (ETE). LIQUIDATED STAKES: Equinix (EQIX), Cameron International (CAM), Dollar General (DG), QEP Resources (QEP), and Amgen (AMGN).
18:06 EDTAGNPaulson & Co gives quarterly update on stakes
Subscribe for More Information
17:18 EDTAGNPershing Square gives quarterly update on stakes
NEW STAKES: Restaurant Brands International (QSR). INCREASED STAKES: Zoetis (ZTS), and Platform Specialty Products (PAH). DECREASED STAKES: Allergan (AGN). LIQUIDATED STAKES: None.
17:13 EDTVRXPoint72 gives quarterly update on stakes
Subscribe for More Information
17:02 EDTAGNSoros Fund Management gives quarterly update on stakes
Subscribe for More Information
16:29 EDTJNJ Boston Scientific announces settltement of merger agreement lawsuit
Subscribe for More Information
13:52 EDTAGNEarnings Preview: Actavis near 52-week high ahead of Q4 earnings report
Subscribe for More Information
07:04 EDTJNJGTx names Robert Wills as executive chairman
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use